Bypass Without Breaking the Breastbone

Key Takeaway: In an international randomized trial of 170 patients, minimally invasive coronary bypass surgery was found to provide significantly better physical recovery at one month compared to traditional open-heart surgery. At one-year follow-up, no cases of death or stroke were observed in either group. These findings offer the strongest evidence to date that a smaller incision translates to a significantly faster return to normal life.

A Quiet Revolution in the Operating Room

For more than half a century, coronary artery bypass grafting surgery—popularly known as heart bypass surgery—has required splitting the breastbone (sternum) down the middle. This incision, which surgeons call a “median sternotomy,” provides unparalleled access to the heart but leaves patients with a long and painful recovery, imposing weeks of restrictions on activities like lifting, driving, and even hugging their grandchildren. Now, an international study confirms what many surgical teams have long suspected: a smaller incision made between the ribs, rather than through the sternum, allows patients to return to their physical lives much sooner without compromising safety.

The MIST Trial in Detail

The MIST (Minimally Invasive versus Sternotomy) trial enrolled 176 patients from seven international centers with multivessel coronary artery blockages severe enough to require bypass surgery; of these, 170 were randomly assigned to either MICS CABG (n=86) or sternotomy CABG (n=84). The two groups were minimally invasive coronary surgery (MICS CABG), performed through a small incision between the ribs on the left side of the chest, or traditional full sternotomy. A critical design strength of the study is that randomization occurred across multiple countries, meaning the results are less likely to be influenced by the unique conditions of a single hospital or a single star surgeon.

The study’s primary endpoint was commendably patient-centered. Instead of measuring graft patency on an angiogram or counting cardiac enzymes in a lab, the researchers asked patients how they actually felt. To do this, they used the SF-36 Physical Component Summary (PCS) score, a validated questionnaire that measures a person’s ability to perform daily activities, climb stairs, carry groceries, and move through the world without limitation^[2]. At one month, patients in the MICS group scored 45.1 on this measure, while those in the sternotomy group scored 42.2. The mean difference of 2.9 points reached statistical significance (p = 0.031)^[1]. In the context of the SF-36, differences of 2 to 3 points on the PCS are considered clinically meaningful, representing a real and perceptible improvement in daily functioning^[3].

The safety data were equally reassuring. During the 12-month follow-up period, there were no deaths or strokes in either group. Only one major adverse cardiac or cerebrovascular event occurred, and this was in the MICS group. This suggests that the minimally invasive approach does not harbor hidden dangers.

Why a Smaller Incision Makes a Bigger Difference

The sternum is not just a flat, bony shield. It is the keystone of the rib cage, anchoring the ribs, supporting the muscles of respiration, and bearing mechanical load every time you cough, twist, or reach. Splitting this bone with a saw triggers an intense inflammatory and repair cascade. Bone healing requires restricted activity for approximately six to eight weeks, and even after radiographic union is achieved, many patients describe persistent sternal discomfort for months^[4]. Although rare, sternal wound complications can be devastating; deep sternal wound infection carries mortality rates as high as 10% to 25% in some series^[5].

Minimally invasive CABG circumvents this entire problem. The surgeon avoids splitting the bone entirely, entering the chest through a small, 6- to 8-centimeter left anterior thoracotomy, typically between the fourth and fifth ribs. Depending on the surgical technique, the intercostal muscles are spread rather than cut, and the left internal mammary artery—the gold-standard vessel for bypass grafting—is harvested under direct or thoracoscopic vision^[6]. Because the structural integrity of the chest wall is preserved, patients can return to upper body activities much sooner. There is less postoperative pain from bone healing, narcotic use is reduced, and seeing a small, discreet scar rather than a long midline wound provides a psychological boost.

The physiologic advantages extend beyond the incision. Multiple observational studies have reported less blood loss, fewer transfusions, and shorter intensive care unit stays with MICS CABG compared to sternotomy^[7]. These factors compound: less blood loss means less anemia-related fatigue; fewer transfusions reduce the risk of immune-mediated complications; and mobilizing out of the ICU sooner lowers the chance of hospital-acquired pneumonia and deconditioning.

Noteworthy Limitations

No single study rewrites the medical textbooks. While the MIST trial, with 170 patients, was sufficiently powered for its primary endpoint, it was too small to detect rare complications like graft failure or late cardiac events with statistical confidence. The 12-month follow-up, while encouraging, is short; longer-term data on graft durability and survival will be essential. Additionally, MICS CABG requires a high level of surgical expertise; the seven centers in this study were experienced, and results at less seasoned institutions may differ. Patient selection is also crucial: not every anatomical pattern of coronary artery disease is equally amenable to a minimally invasive approach.

What These Findings Mean for Tomorrow’s Patients

For a person sitting in a cardiologist’s office hearing the words “you need bypass surgery,” the MIST trial offers a concrete, evidence-based starting point for dialogue. The data show that, at experienced centers, minimally invasive bypass surgery provides a faster return to physical function during the first, most difficult month of recovery, without compromising the safety that has made CABG a cornerstone of cardiac therapy for decades. This 2.9-point advantage on the SF-36 score translates into tangible real-world gains: climbing a flight of stairs with less pain, lifting a bag of groceries a week sooner, sleeping comfortably without a fractured breastbone knitting together beneath the skin. As more surgical teams master this technique and longer-term data accumulate, MICS CABG is poised to become not just an alternative, but the preferred approach for appropriately selected patients with multivessel coronary disease.

Scientific Sources

1. Ruel M, et al. Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial. Lancet (London, England). 2026;408(10556):711-720. PubMed: https://pubmed.ncbi.nlm.nih.gov/42537680/
2. Garratt A, et al. Measurement properties and normative data for the Norwegian SF-36: results from a general population survey. Health Qual Life Outcomes. 2017. DOI: 10.1186/s12955-017-0625-9
3. Samsa G, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999. DOI: 10.2165/00019053-199915020-00003
4. El-Ansary D, et al. An Evidence-Based Perspective on Movement and Activity Following Median Sternotomy. Phys Ther. 2019. DOI: 10.1093/ptj/pzz126
5. Lazar HL, et al. Prevention and management of sternal wound infections. J Thorac Cardiovasc Surg. 2016. DOI: 10.1016/j.jtcvs.2016.01.060
6. McGinn JT, et al. Minimally invasive coronary artery bypass grafting: dual-center experience in 450 consecutive patients. Circulation. 2009. DOI: 10.1161/CIRCULATIONAHA.108.840041
7. Teman NR, et al. Minimally Invasive versus Open Coronary Surgery: A Multi-Institutional Analysis of Cost and Outcomes. Ann Thorac Surg. 2021. DOI: 10.1016/j.athoracsur.2020.06.136